NuCana Aktie - NCNA

Professionelle Tools für Privatanleger.

Premium

Current Price

0,935

Gebot

0,90

Fragen

1,20

Volumen

25.798

0,898299 Tagesbereich 0,97

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

2,104M

Handelsende

0,9282

Handelsbeginn

0,9282

Letzte Trade

177

0.935

(formt)

Letzter Handelszeitpunkt

Finanzvolumen

US$ 23.990

VWAP

0,929922

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

2.250.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-0,08

Gewinn pro Aktie (EPS)

-12,28

Erlöse

Nettogewinn

-27,63M

NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of ... NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Hauptsitz

London, Gbr

Gegründet

NuCana PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NCNA. The last closing price for NuCana was US$0,93. Over the last year, NuCana shares have traded in a share price range of US$ 0,00 to US$ 0,00.

NuCana currently has 2.250.000 shares in issue. The market capitalisation of NuCana is US$2,09 million. NuCana has a price to earnings ratio (PE ratio) of -0.08.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

NCNA - Frequently Asked Questions (FAQ)

What is the current NuCana share price?

The current share price of NuCana is US$ 0,935

How many NuCana shares are in issue?

NuCana has 2.250.000 shares in issue

What is the market cap of NuCana?

The market capitalisation of NuCana is USD 2,09M

What is the 1 year trading range for NuCana share price?

NuCana has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of NuCana?

The price to earnings ratio of NuCana is -0,08

What is the reporting currency for NuCana?

NuCana reports financial results in GBP

What is the latest annual profit for NuCana?

The latest annual profit of NuCana is GBP -27,63M

What is the registered address of NuCana?

The registered address for NuCana is 77 78 CANNON STREET, ENGLAND, LONDON, EC4N 6AF

Which industry sector does NuCana operate in?

NuCana operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
STAKSTAK Inc	US$ 3,97 (156,13%)	174,23k
ORGOOrganogenesis Holdings Inc	US$ 6,21 (102,28%)	59M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
ARBBARB IOT Group Ltd	US$ 0,6635 (38,23%)	59,08M
NVNINVNI Group Ltd	US$ 0,99 (-50,50%)	72,28M
SPGCSacks Parente Golf Inc	US$ 0,2085 (-48,65%)	57,4M
ADGMAdagio Medical Holdings Inc	US$ 0,8081 (-47,53%)	756,64k
PRAXPraxis Precision Medicines Inc	US$ 38,60 (-40,64%)	3,17M
SAGSAG Holdings Ltd	US$ 1,19 (-38,97%)	788,89k
NVDANVIDIA Corporation	US$ 124,92 (3,97%)	389,48M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 13,44 (7,78%)	154,46M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
LCIDLucid Group Inc	US$ 2,22 (-0,45%)	136,17M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NuCana PLC (NCNA) Börsenkurse

NuCana PLC (NCNA)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über NuCana PLC

NCNA Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NCNA - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR